Abstract
Impaired cardiac relaxation, or diastolic dysfunction, is a key contributor to heart failure in diabetic patients, making early detection critical for preventing disease progression. This review explores current diagnostic modalities for assessing myocardial relaxation function in diabetes-associated HFpEF, including imaging techniques, biomarker analysis, and emerging chip-based technologies. We highlight advancements in echocardiography, cardiac MRI, molecular diagnostics, and innovative microfluidic and biosensor-based devices that offer real-time monitoring of myocardial relaxation dynamics. Integrating these diverse modalities holds promise for enhancing early diagnosis and enabling personalized therapeutic approaches to improve patient outcomes.